A RANDOMISED, OPEN-LABEL PHASE II TRIAL OF VOLASERTIB AS MONOTHERAPY AND IN COMBINATION WITH STANDARD DOSE PEMETREXED COMPARED WITH PEMETREXED MONOTHERAPY IN SECOND-LINE NON-SMALL CELL LUNG CANCER (NSCLC) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Ellis, Peter
  • Leighl, Natasha
  • Hirsh, Vera
  • Reaume, MN
  • Blais, Normand
  • Wierzbicki, Rafal
  • Sadrolhefazi, Behbood
  • Gu, Yu
  • Liu, Dan
  • Pilz, Korinna
  • Chu, Quincy

publication date

  • November 1, 2013